Alpha Wealth Funds, LLC, an investment management company, released its Q1 2025 letter for the “Insiders Fund”. A copy of the letter can be downloaded here. The fund lost 7.14% in the quarter, tied to a 6.75% fall in March due to the War in Iran. This compares to the S&P 500’s -4.33% return for the same period. The losses are mainly unrealized, and the firm is evaluating its long-term thesis and risk-adjusted opportunities. The Fund considers the current situation as unfavorable. In addition, please check the fund’s top five holdings to know its best picks in 2026.
In its first-quarter 2026 investor letter, Alpha Wealth Insiders Fund highlighted stocks like Abbott Laboratories (NYSE:ABT). Abbott Laboratories (NYSE:ABT) is a global healthcare company that develops and manufacturers medical devices, diagnostics and nutritional products. On May 21, 2026, Abbott Laboratories (NYSE:ABT) closed at $87.77 per share. One-month return of Abbott Laboratories (NYSE:ABT) was -3.69%, and its shares lost 33.15% over the past 52 weeks. Abbott Laboratories (NYSE:ABT) has a market capitalization of $152.88 billion.
Alpha Wealth Insiders Fund stated the following regarding Abbott Laboratories (NYSE:ABT) in its Q1 2026 investor letter:
“Business: Abbott Laboratories (NYSE:ABT) is a global healthcare leader focused on life-changing technologies. Founded in 1888, the company operates across four primary segments: Diagnostics, Medical Devices, Established Pharmaceuticals, and Nutrition. Abbott is widely recognized for its “Dividend King” status, having increased its dividend for over 50 consecutive years. Key products include the FreeStyle Libre glucose monitoring system and the BinaxNOW rapid tests.
Insider Buying: CEO and Chairman Robert Ford bought $2 million worth of shares on 1-23-26 at $107.13. He was followed by Director Starks with 10,000 shares on 2-24-26 at $108.73 per share.
Recent News: ABT was down 7.5% after Q1 earnings miss. Shares hit a 52-week low near $100.85 in early April. While the company is meeting EPS targets, revenue growth in some sectors has been slightly lower than hoped, leading to a “Moderate Buy” consensus as the market waits for the Exact Sciences (Colo guard) integration to show results. The Class 1 recall on Feb 4th for some of their leading market share FreeStyleLibre 3 seems to be already priced in the stock. Director Stark’s $1 million purchase added to his significant holdings, 6.7Million shares. Starks is an attorney by profession and former CEO and Chairman of St.Jude Medical, an Abbott acquisition in 2017….” (Click here to read the full text)
Abbott Laboratories (NYSE:ABT) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 71 hedge fund portfolios held Abbott Laboratories (NYSE:ABT) at the end of the fourth quarter, up from 68 in the previous quarter. While we acknowledge the risk and potential of Abbott Laboratories (NYSE:ABT) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Abbott Laboratories (NYSE:ABT) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered Abbott Laboratories (NYSE:ABT) and shared the list of stocks Jim Cramer discussed. In addition, please check out our hedge fund investor letters Q1 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
